Fig. 7. WEHI-7326 prolongs survival in mouse models of high-risk neuroblastoma and leads to complete tumor regression when used in combination with standard-of-care relapse therapies.

Tumor growth curve (a) and Kaplan–Meier survival plot (b) of relapsed HR NB PDX model COG-N-496x treated with either vincristine (0.5 mg/kg, i.p.; once) or WEHI-7326 (20 mg/kg, i.v.; twice a week). p(vincristine) = 0.3741 (ns), p(WEHI-7326) = 0.0023 (**) compared to vehicle control; p-values obtained through Log-rank (Mantel-Cox) test, n = 8 mice. Tumor growth curve (c) and Kaplan–Meier survival plot (d) of refractory HR NB PDX COG-N-440x. p(vincristine) = 0.3602 (ns), p(WEHI-7326) <0.0001 (****) compared to vehicle control; p-values obtained through Log-rank (Mantel-Cox) test, n = 8 mice. e Kaplan–Meier survival plot of Th-MYCN transgenic model: spontaneous neuroblastoma driven by targeted expression of human MYCN in the developing mouse neural crest under control of the rat tyrosine hydroxylase (TH) promoter. Tumor growth was assessed by abdominal palpation and mice were euthanized at a medium palpable tumor of 1 cm³. Treatment schedules were vehicle control (saline); WEHI-7326 (20 mg/kg; twice weekly for 5 weeks; i.v.); cyclophosphamide (10 mg/kg, daily i.p.); topotecan (0.5 mg/kg, daily IP); irinotecan (2 mg/kg, daily, i.p.) and temozolomide (5 mg/kg, daily, i.p.). Mice that are surviving on this graph past 100 day showed no evidence of disease. Displayed p-value was obtained through Log-rank (Mantel-Cox) test.